Short answer
Tango Therapeutics, Inc. (TNGX) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 (down 100.0% year over year) with net income of −$68M.
Q3 2026 key financials · XBRL
- Revenue
- $0
- −100.0% YoY
- Net income
- −$68M
- −530.6% YoY · −23.6% QoQ
- EPS (diluted)
- −$0.40
- −385.7% YoY · −11.1% QoQ
Source: XBRL data from the Tango Therapeutics, Inc. (TNGX) Q3 2026 10-Q on SEC EDGAR. USD.
Tango Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly collaboration revenue $0, down $53.8M YoY from Gilead recognition
- Net loss $68.4M vs net income $15.9M YoY; operating margin not disclosed
- Vopimetostat plus daraxonrasib: 82% ORR and 88% nine-month PFS in 22 PDAC patients
- Cash, equivalents and marketable securities $977.5M; operating cash use $120.4M through nine months
- Outlook: $977.5M funds operations at least twelve months; registrational trial expected first half 2027
Risk Factors
- New combination-supply risk: daraxonrasib supply uncertainty threatens planned global registrational trial in first half of 2027
- Regulatory risk: third-party combination drugs may lack regulatory approval or remain unavailable for clinical and commercial use
- Operational risk: failure to secure daraxonrasib could delay development timelines
- Financial risk: purchasing checkpoint inhibitors or comparator therapies may increase development costs
- Partnership risk: loss of collaborations with Revolution Medicines, Lilly, or Erasca could disrupt combination trials
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Tango Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.